Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07226154 · ClinicalTrials.gov registry record
Prediction of Neoadjuvant Chemotherapy Response in Pancreatic Cancer
A clinical trial of Pancreatic Ductal Adenocarcinoma, sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT07226154: Recruiting study of Pancreatic Ductal Adenocarcinoma, sponsored by City of Hope Medical Center.
NCT07226154 is a study of Pancreatic Ductal Adenocarcinoma that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 200 participants, below the 598-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07226154, a study of Pancreatic Ductal Adenocarcinoma, is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to develop and validate a predictive microRNA (miRNA) panel to assess the response to neoadjuvant chemotherapy (NACT) in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma (PDAC).
Primary Outcome
Proportion of patients achieving partial or complete pathologic response after neoadjuvant chemotherapy, as assessed using resected pancreatic cancer specimens.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Small RNA sequencing
- DIAGNOSTIC_TEST PRECEPT assay (qRT-PCR validation)
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-11-15 |
| Est. Completion | 2026-06-18 |
What NCT07226154 shows while recruiting
NCT07226154 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 598-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Pancreatic Ductal Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Small RNA sequencing is the first listed.
NCT07226154 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07226154 about?
NCT07226154 is a clinical study titled "Prediction of Neoadjuvant Chemotherapy Response in Pancreatic Cancer". This study aims to develop and validate a predictive microRNA (miRNA) panel to assess the response to neoadjuvant chemotherapy (NACT) in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma (PDAC).
What is the current status of trial NCT07226154?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2024-11-15. Estimated completion is 2026-06-18.
What conditions does trial NCT07226154 study?
This clinical trial studies the following conditions: Pancreatic Ductal Adenocarcinoma.
What interventions are being tested in trial NCT07226154?
The interventions under investigation include: Small RNA sequencing (DIAGNOSTIC_TEST), PRECEPT assay (qRT-PCR validation) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07226154?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07226154 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Ductal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07226154's enrollment target sits among peer trials
200 29th of 84 higher than 55 of 84 other Pancreatic Ductal Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Ductal Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer
RECRUITING · Phase 2
-
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
RECRUITING · Phase 1
-
A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy
RECRUITING
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI